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Background: Increasing rates of percutaneous coronary intervention (PCI) and decreasing rates of coronary artery
bypass graft (CABG) surgery followed the introduction of drug eluting stents in Western Australia in 2002. We
assessed the impact of these changes on one-year outcomes for the total population of patients undergoing
coronary artery revascularisation procedures (CARP) in Western Australia between 2000-2004.
Methods: Clinical and linked administrative data (inpatient admissions and death) were merged for all patients
who had their first CARP with stent or CABG in Western Australia between 2000-2004. The clinical data were
collected from all hospitals in Western Australia where CARP procedures are performed. We calculated the
unadjusted (Kaplan-Meier) and adjusted (Cox) risks for one-year death (all-cause), death (all-cause) or admission for
myocardial infarction (MI), target vessel revascularisation (TVR) and the composite outcome of death/MI/TVR (major
adverse cardiac events, MACE).
Results: Over the study period, there were 14,118 index CARPs. The use of drug eluting stents increased from 0%
to 95.8% of PCI procedures, and PCI procedures increased from 61.1% to 74.4% of all CARPS. There were no
temporal changes in adjusted one-year mortality or death/MI. Overall, adjusted one-year MACE fell from 11.3% in
2000 to 8.5% in 2004 (p<0.0001) due to a significant reduction in TVR in the PCI group.
Conclusion: The introduction of drug eluting stents and resulting changes in coronary revascularisation strategies
were not associated with changes in the one-year risk of major clinical endpoints (death or death/MI), but were
associated with a significant reduction in the risk of MACE, driven entirely by a reduction in TVR after PCI. This real
world study supports the effectiveness of drug eluting stents in reducing repeat procedures in the total CARP
population without increasing the risk of death or MI.
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Coronary artery revascularisation procedures (CARP)
using percutaneous coronary intervention (PCI) or sur-
gical (coronary artery bypass graft, CABG) techniques
are commonly performed for patients with significant
obstructive coronary artery disease to relieve angina, im-
prove survival or both. Over the last 30 years, there has
been stepwise improvement in revascularisation tech-
niques, with a significant increase in the proportion of
patients treated percutaneously [1]. Medical therapies
have also improved significantly over this period. It is
often difficult to assess the relative effectiveness and
real-world safety of new techniques, with guidance usu-
ally coming from case series, registries and randomised
controlled trials. Most of these studies examine either
PCI or CABG or, in some cases, direct comparisons be-
tween different revascularisation strategies in selected
populations [2-4]. Another method for assessing the im-
pact of a new therapy is to examine population-based
outcomes as the new therapy is introduced to an other-
wise stable population. Such a study demonstrated im-
proved outcomes following PCI as coronary stents were
introduced into British Columbia in the mid-1990s [5].
As a new PCI technology, drug eluting stents (DES)
became widely used in Western Australia from mid-
2002 following clinical trials demonstrating the efficacy
of DES in reducing clinical events [6,7]. This provided
us with a unique opportunity to examine the real-world
impact of DES by linking routinely collected State-wide
health administrative data from the Western Australian
Data Linkage System [8] with clinical registries covering
all coronary revascularisation procedures. Our intention
was to assess the impact of changing revascularisation
strategies on outcomes following the release of DES in
the total population of patients undergoing coronary ar-
tery revascularisation procedures, rather than to directly
compare DES or PCI with CABG.
Methods
Participating hospitals and study population
In Western Australia (population 1.95 million in 2003),
CARPs are carried out exclusively in the three adult
teaching hospitals and in four private hospitals, all lo-
cated in the Perth metropolitan area. Loss of cases to
Centres in other States (located at least 2000 km distant)
is considered to be very rare. The study population
consisted of all patients who had a PCI or CABG pro-
cedure at any of these Perth hospitals during 2000 to
2005. Patients with out-of-State postcodes were ex-
cluded. There was no restriction on age. The PCI cases
were limited to those who had stents, divided into pro-
cedures for bare metal stents (BMS) only or DES (with
or without BMS). The cohorts included patients with left
main disease as well as multi-vessel disease.Data sources and variables
Clinical data for PCI procedures were obtained from the
seven hospitals and linked to records of hospital admis-
sions (Hospital Morbidity Data Collection, HMDC) and
death, which are two of the core datasets of the Western
Australian Data Linkage System [8]. Records were
matched using the patient’s unique medical record num-
ber, procedure date and hospital identifier code. CABG
procedures in 2000-2005 were identified from the
HMDC using codes from blocks 672-679 in the Inter-
national Classification of Diseases (ICD) 10th revision
Australian Modification. The data included the number
of vessels grafted and whether venous or arterial grafts
were used. The CABG file was combined with the PCI
file to provide a dataset of total CARPs for the 6-year
period 2000-2005.
Details of PCI procedures from private hospitals were
collected from billing sheets, computer databases (if avail-
able), medical notes (cardiologist or hospital notes),
radiographer’s journal, nursing intervention records, as well
as the cardiologist’s operation notes. Data from teaching
hospitals were obtained from clinical databases maintained
by cardiology departments with their own internal data
checking procedures. Missing or inconsistent data were
queried with cardiac catheter laboratory personnel of the
corresponding hospital, and amended where possible.
The aggregated minimum dataset of PCI and CABG
cases included: residential postcode, age, gender, admis-
sion and discharge dates, type of hospital, type of admis-
sion, discharge diagnosis and procedure codes (for
current diagnosis and medical history), procedure date
and time, vessels treated, number of grafts, type of grafts
used, number and details of stents inserted (name, diam-
eter, length), and date and cause of death.
Treatment groups
Patients were classified as either index PCI or index
CABG in 2000-2004 by applying a fixed look-back
period of 5 years to the linked HMDC records to iden-
tify the first admission for PCI or CABG in 2000-2004.
We limited the index cohort to 2000-2004 so that each
person would have at least 12 months of follow-up. If a
patient had both a PCI and CABG in the same index ad-
mission (n=52), we assigned them according to which
procedure came first, and excluded 22 cases who had
balloon angioplasty first or were missing data for the
PCI type, leaving 30 cases with PCI (stents) plus CABG.
The cohort is part of a current long-term follow-up, and
here we report results of outcomes/endpoints in the first
year of follow-up. Rather than comparing PCI and CABG,
our study has investigated the total revascularisation cohort
to determine whether the introduction of a new
revascularisation technology has changed outcomes in the
whole population of patients who had these procedures.
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Outcomes and endpoints were assessed over one year
for index CARP cases and included: (i) all-cause death;
(ii) all-cause death or admission for MI (whichever was
first); (iii) target vessel revascularization (TVR); and (iv)
major adverse cardiac events (MACE) defined as all-
cause death or MI admission or TVR, whichever was
first. For index PCI cases, a TVR endpoint was defined
as a subsequent PCI procedure on the same vessel as in
the index PCI (as identified from clinical data), or as any
subsequent CABG procedure, whichever was first. For
index CABG cases, a TVR endpoint was any subsequent
PCI or CABG procedure. Follow-up ceased on the date
of an outcome/endpoint within 12 months of the index
date or at the end of the 12-month period. Patients were
censored if the outcome/endpoint did not occur during
follow-up. There were too few one-year stroke events
(91 in total) for a separate analysis of this outcome over
time in any of the revascularisation cohorts. We have
also reported 28-day mortality as part of the characteris-
tics of the index admissions in the total revascularisation
cohort.
Comorbidities
The HMDC was used to identify previous admissions
within 5 years of the index CARP where the discharge
diagnosis was recorded as MI, stroke, diabetes, renal fail-
ure, congestive heart failure, peripheral vascular disease
or chronic obstructive pulmonary disease in any diagno-
sis field. Similarly, a Charlson comorbidity score [9] was
calculated for each index case by applying a fixed 5-year
look-back period using the HMDC, excluding MI in the
calculation of the score if it occurred in the index CARP
admission. We used the Dartmouth-Manitoba ICD code
assignments [10] in calculating the Charlson score based
on the original 17 Charlson comorbidities.
Statistical methods
To show the changing trends and uptake of all CARPs
in Western Australia during 1980-2005, we plotted the
age-standardised rates of admission for CARPs in males
aged 35 years or older (males and females had similar
trends). Rates were age-standardised by the direct method
using the age distribution of the Western Australian
resident population at 30 June 2001 (a census year) as the
standard [11].
The Charlson comorbidity score was compared be-
tween index PCI and CABG using the Wilcoxon
two-sample test with Normal approximation and con-
tinuity correction. Counts of one-year outcomes/end-
points are presented for each treatment group by year of
index admission, and one-year unadjusted risks were esti-
mated from corresponding Kaplan-Meier survival prob-
abilities at 12 months. Temporal changes in unadjustedrisks were assessed using the two-sided log-rank test across
years.
Cox proportional hazards regression was used to esti-
mate the adjusted risk for the outcomes/endpoints over
the first 12 months by index year of admission separately
for CABG, PCI and total CARPs. The models were ad-
justed for age, gender, Charlson comorbidity score, prin-
cipal diagnosis at index admission, type of index
admission (emergency, booked), type of hospital at index
admission, number of vessels treated (single, multiple),
and type of CARP (for the All CARPs models only). The
year of admission variable in all Cox models was tested
for and passed the proportional hazards assumption in-
dicating that the relative risk of the outcome/endpoint
did not change over the 12 month follow-up period for
the index years. The same models were used to estimate
the adjusted hazard ratio (HR) and 95% confidence
interval for year of index admission and each adjustment
variable in the total CARP cohort, and to plot adjusted
survival curves for the outcome of MACE.
Ethics approval
The study complies with the Declaration of Helsinki, and
was approved by human research ethics committees of
participating hospitals, the University of Western Australia
and the Confidentiality of Health Information Committee
of the Western Australian Department of Health. Being a
large population-based epidemiological study, the approval
included a waiver of informed consent.
Results
Trends in revascularisation procedures
Figure 1 provides context to the long-term trends in cor-
onary revascularisation in Western Australia since the
introduction of CABG in the late 1970s and PCI in
1983. CARP rates increased throughout, with rates
slowing from 1993, but increasing again from 1998.
Rates of PCI surpassed those for CABG in 1994 after
which the latter steadily declined. BMS were available
from 1992 in Western Australia and rapidly replaced
percutaneous transluminal coronary (balloon) angio-
plasty (PTCA). DES were introduced in mid-2002 (25%
of PCI procedures) and largely replaced BMS by 2004
(95% of PCI procedures). This was accompanied by a
further noticeable increase in the rate of PCI.
Demographic and clinical characteristics
Table 1 shows demographic and clinical information for
the 14,118 patients with index CARPs, consisting of
5174 patients with BMS, 4419 with DES and 4525 with
CABG. The total count of procedures increased from
2669 in 2000 to 3088 in 2004, with much of the increase
attributable to an increase in emergency admissions or
in cases with a principal diagnosis of MI. However, there
Figure 1 Age-standardised rates of admission for coronary artery revascularisation procedures in males aged 35 years or older in
Western Australia during 1980-2005. CARP = total PCI + CABG; Total PCI = Stents + PTCA; PTCA, percutaneous transluminal coronary (balloon)
angioplasty. Curves for females show a similar pattern. Although stents were available in Western Australia in 1988, there was little uptake until
1994, and there was no ICD-9-CM code until July 1995.
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history of admission for MI. The total cohort had a
mean age of 64 years, 76% were male, and persons
undergoing CABG were significantly older and more
likely to be male than those receiving PCI. Comorbidity,
as measured by the Charlson score, did not change
much over time, but CABG cases had a higher mean
Charlson score than PCI cases. The majority of cases
overall (67%) were single vessel disease, but only 25%
of the CABG cohort had single-vessel disease com-
pared with 86% in the PCI cohort. Arterial grafts
were used slightly more than venous grafts in all
years from 2000-2004, and the majority of CABG pa-
tients had both venous and arterial grafts used in the
procedure. Deaths within 28 days of index admission
occurred in 2% of the CARP cohort, with the propor-
tion higher for CABG procedures than PCI (3.2% ver-
sus 1.4%) and lowest for DES procedures (1.1%). The
majority of procedures were in public hospitals and
consisted mainly of booked admissions rather than
emergency.
Outcomes
Trends in adverse outcomes/endpoints (death, MI, TVR)
within 12 months of index CARP are shown in Table 2
for each type of procedure, including estimates of one-
year risk from Kaplan-Meier curves (unadjusted) and
Cox regression models (adjusted), with corresponding
Cox adjusted survival curves shown in Figure 2. For all
CARP, there were no changes over time in the risk of
major clinical endpoints (death or death/MI), but there
was a marked and significant decline in TVR reflected
also in the composite endpoint (MACE). The risk ofdeath was higher in the CABG cohort than PCI, but
risks were similar for death/MI, with no consistent
trends over time. The PCI cohort had much higher un-
adjusted and adjusted risks for the technical endpoint
(TVR) compared to the CABG cohort. However, the risk
of TVR following PCI halved from 2000 to 2004
(p<0.0001) during the transition from BMS to DES. The
risk of TVR following CABG was low and did not
change over time. The unadjusted and adjusted risks of
MACE declined significantly for the PCI group, but
there was no clear trend in the CABG group. Overall
for CARPS, there was a significant decline in un-
adjusted and adjusted risk of MACE over time which
was driven by the decline in the PCI group. These re-
sults did not change after we excluded the 30 cases
who had PCI (stents) plus CABG in their index admis-
sion. Whilst the survival curves (Figure 2) showed a
gradual decline in the PCI group throughout the one-
year follow-up, events were more likely to occur in the
first 30 days in the CABG group. These analyses were
repeated in the sub-cohorts of patients with multi-
vessel disease. Trends in 12-month outcomes were
similar to those of the total PCI and CABG cohorts
reported in Table 2, with higher unadjusted and ad-
justed risks seen in the PCI subcohort with multi-vessel
disease, and slightly higher risks in the CABG
subcohort with multi-vessel disease (see Additional file
1: Table S2).
Table 3 shows adjusted HRs for one-year outcomes/
endpoints from Cox regression models. As in Table 2,
the “risk” or hazard of death and death/MI did not
change by calendar year, but there was a marked decline
in hazard for TVR between 2000-2002 and 2003-2004.
Table 1 Patient characteristics at index admission for PCI (excluding angioplasty only) and CABG during 2000-2004
2000 2001 2002 2003 2004 Total
Number of patients (col%) 2669 2652 2765 2944 3088 14118
BMS 1630 (61.1) 1725 (65.0) 1370 (49.6) 353 (12.0) 96 (3.1) 5174
DES ¶ 0 0 486 (17.6) 1733 (58.9) 2200 (71.2) 4419
CABG 1039 (38.9) 927 (35.0) 909 (32.9) 858 (29.1) 792 (25.6) 4525
Age
mean (SD) 63.7 (11.1) 63.8 (11.1) 64.2 (11.7) 64.0 (11.8) 64.3 (11.6) 64.0 (11.5)
range 27-93 30-92 27-94 26-93 30-93 26-94
Males (%) 76.0 77.0 76.4 76.6 75.6 76.3
Main diagnosis, MI (%) † 550 (20.6) 588 (22.2) 798 (28.9) 901 (30.6) 998 (32.3) 3835 (27.2)
Prior disease, no. (%) ‡
MI 572 (21.4) 511 (19.3) 532 (19.2) 583 (19.8) 509 (16.5) 2707 (19.2)
Stroke 51 (1.9) 41 (1.6) 37 (1.3) 30 (1.0) 44 (1.4) 203 (1.4)
Diabetes 434 (16.3) 469 (17.7) 493 (17.8) 572 (19.4) 558 (18.1) 2526 (17.9)
Renal failure 72 (2.7) 71 (2.7) 84 (3.0) 124 (4.2) 114 (3.7) 465 (3.3)
Congestive heart failure 222 (8.3) 182 (6.9) 192 (6.9) 225 (7.6) 191 (6.2) 1012 (7.2)
COPD 223 (8.4) 204 (7.7) 163 (5.9) 149 (5.1) 132 (4.3) 871 (6.2)
PVD 156 (5.8) 156 (5.9) 126 (4.6) 174 (5.9) 144 (4.7) 756 (5.4)
Charlson score (mean) § 1.38 1.36 1.31 1.39 1.31 1.35
Number of vessels treated, no. (%) ††
single 1688 (65.4) 1704 (66.3) 1829 (67.6) 1954 (67.9) 2047 (68.2) 9222 (67.1)
multi-vessel 891 (34.6) 867 (33.7) 876 (32.4) 925 (32.1) 956 (31.8) 4515 (32.9)
Patients with venous grafts in CABG cohort, n (%) # 853 (82.1) 755 (81.5) 746 (82.1) 722 (84.2) 675 (85.2) 3751 (82.9)
Patients with arterial grafts in CABG cohort, n (%) # 924 (88.9) 816 (88.0) 795 (87.5) 768 (89.5) 712 (89.9) 4015 (88.7)
Deaths within 28 days, no. (%) 53 (2.0) 45 (1.7) 58 (2.1) 41 (1.4) 80 (2.6) 277 (2.0)
Hospital type: public, no. (%) 1728 (64.7) 1668 (62.9) 1674 (60.5) 1791 (60.8) 1828 (59.2) 8689 (61.6)
Admission type: emergency, no. (%) 1008 (37.8) 1013 (38.2) 1100 (39.8) 1223 (41.5) 1366 (44.2) 5710 (40.4)
CABG coronary artery bypass graft surgery, PCI percutaneous coronary intervention, BMS bare metal stent, DES drug eluting stent; col%, column percent, SD
standard deviation, MI myocardial infarction.
¶ DES are with or without BMS, and were first used in mid-2002 in Western Australia.
† Significant increasing trend during 2000-2004 in the proportion of MI as main discharge diagnosis (p<0.0001; Cochran-Armitage trend test).
‡ History of admissions for disease within 5 years of index admission for CABG or PCI. COPD, chronic obstructive pulmonary disease; PVD, peripheral
vascular disease.
§ Charlson comorbidity score based on comorbidities within previous 5 years up to and including index admission, but excluding MI in the index admission. Mean
Charlson score significantly higher in index CABG patients (p<0.0001 for each year; Wilcoxon two-sample test using Normal approximation with
continuity correction).
†† For CABG these were identified from ICD codes for procedures recorded in the Hospital Morbidity Data Collection. Some data were missing for both PCI
and CABG.
# Venous grafts are saphenous or other vein grafts; arterial grafts are internal mammary artery (left or right), radial artery or epigastric artery grafts.
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Charlson score, emergency admission and number of
vessels treated. The risk of TVR increased with Charlson
score, emergency admission, and number of vessels
treated, was borderline for age and principal diagnosis of
MI, and was reduced for admission to public hospitals.
The risk of death within 12 months was lower following
PCI than CABG ((HR 0.75, 95% confidence interval (CI)
0.60, 0.94). However, the risk of TVR or MACE was
higher in PCI than CABG (HR 8.15, 95% CI 6.05, 10.97;
and HR 2.37, 95% CI 2.03, 2.78, respectively).Discussion
Age standardised rates of CARP have steadily increased
in Western Australia since 1980. Bare metal stents were
introduced into Western Australia in 1988 as a bailout
strategy for complicated balloon angioplasty and their
use increased through the early 1990s, becoming a pri-
mary strategy for PCI by the mid-1990s. This increase in
BMS use was associated with a period of accelerated
growth in total CARP driven by an increase in PCI while
there was a modest decline in rates of CABG. The intro-
duction of DES in 2002 was similarly associated with a
Table 2 One-year outcomes/endpoints by calendar year for 2000-2004 by type of revascularisation
2000 2001 2002 2003 2004 p-value
ALL CARPS (PCI, CABG)
Number of events (unadjusted one-year risk in %)*
Death 104 (3.9) 101 (3.8) 111 (4.0) 98 (3.3) 139 (4.5) 0.22
Death/MI 164 (6.1) 152 (5.7) 166 (6.0) 151 (5.1) 205 (6.6) 0.15
TVR 193 (7.4) 190 (7.3) 154 (5.7) 136 (4.7) 145 (4.8) <0.0001
MACE 331 (12.4) 312 (11.8) 294 (10.6) 260 (8.8) 320 (10.4) 0.0002
Adjusted one year risk in %**
Death 2.3 2.2 2.4 2.0 2.7 0.18
Death/MI 4.6 4.1 4.4 3.7 4.8 0.12
TVR 6.1 5.8 4.4 3.4 3.3 <0.0001
MACE 11.3 10.4 9.4 7.4 8.5 <0.0001
PCI
Number of events (unadjusted one-year risk in %)*
Death 46 (2.8) 52 (3.0) 63 (3.4) 74 (3.5) 95 (4.1) 0.18
Death/MI 95 (5.8) 99 (5.7) 107 (5.8) 123 (5.9) 157 (6.8) 0.50
TVR 180 (11.2) 176 (10.4) 145 (8.0) 127 (6.2) 129 (5.8) <0.0001
MACE 251 (15.4) 248 (14.4) 228 (12.3) 224 (10.7) 257 (11.2) <0.0001
Adjusted one year risk in %**
Death 1.8 1.9 2.0 1.9 2.3 0.67
Death/MI 4.5 4.4 4.3 4.1 4.9 0.69
TVR 11.0 10.3 7.9 6.0 5.6 <0.0001
MACE 14.5 13.5 11.6 9.6 10.1 <0.0001
CABG
Number of events (unadjusted one-year risk in %)*
Death 58 (5.6) 49 (5.3) 48 (5.3) 24 (2.8) 44 (5.6) 0.04
Death/MI 69 (6.6) 53 (5.7) 59 (6.5) 28 (3.3) 48 (6.1) 0.02
TVR 13 (1.3) 14 (1.6) 9 (1.0) 9 (1.1) 16 (2.1) 0.34
MACE 80 (7.7) 64 (6.9) 66 (7.3) 36 (4.2) 63 (8.0) 0.02
Adjusted one year risk in %**
Death 3.4 2.8 3.3 1.9 3.8 0.08
Death/MI 4.4 3.5 4.3 2.4 4.5 0.04
TVR 1.1 1.6 0.9 1.0 2.0 0.27
MACE 5.7 4.9 5.4 3.3 6.4 0.03
MI myocardial infarction, TVR target vessel revascularisation, MACE major adverse cardiac events (death/MI/TVR). * Number of events are counts, and percent in
parentheses is the unadjusted one-year risk (survival probability calculated from the Kaplan-Meier estimate at 1 year. P-value is from log-rank test across years).
** Adjusted one-year risk (%) is the survival probability calculated from the fitted multivariate Cox model for 2000-2004 that includes calendar year, age, Charlson
score, gender, index principal discharge diagnosis, type of index admission, type of hospital, number of vessels treated and type of CARP (only for All CARPs data).
P-value is from Type 3 Wald test for calendar year from the fitted Cox model.
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complete substitution of BMS with DES and further de-
clines in rates of CABG. In each case, the introduction
of new stent technology allowed some patients previ-
ously only suitable for CABG, and others only suitable
for medical therapy, to be treated percutaneously with
PCI.
At a population level, the introduction and widespread
use of DES might improve outcomes by: (i) reducingadverse events after PCI; (ii) allowing treatment of those
previously unsuitable for revascularisation; and (iii)
allowing percutaneous treatment of high-risk surgical
patients. However, it is also possible that outcomes could
deteriorate due to: (i) increased stent thrombosis, MI
and death; (ii) increased bleeding related to dual
antiplatelet therapy; and (iii) increased adverse events in
those treated percutaneously who may have been better
treated surgically.
Figure 2 Cox adjusted survival curves by year 2000-2004 showing
the one-year outcome of MACE (major adverse cardiac events) in
the revascularisation cohort (A-C). The adjusting variables were age,
gender, Charlson comorbidity score, principal diagnosis at index
admission, type of index admission (emergency, booked), type of
hospital at index admission, number of vessels treated (single,
multiple), and type of CARP (for the All CARP models only).
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year outcomes for all CARP (PCI and CABG) over the
period before and after the introduction of DES into
Western Australia. We have shown that in the total
CARP population: (i) there were no temporal changes in
the risk of major clinical endpoints (death or death/MI),
and (ii) there was a marked reduction in the one-year
risk of TVR and MACE over time for the total CARP
population, driven by a significant reduction in TVR in
the PCI cohort with little change in the CABG cohort.
These results support the effectiveness and safety of
DES in reducing adverse events following PCI in a real
world setting. In addition, the increase in total CARP
rates and reduced proportion treated surgically was not
associated with an increase in death or MI, further
supporting the safety of this change in practice of coron-
ary revascularisation.
Late stent thrombosis with DES remains a controver-
sial issue. Previous meta-analyses have suggested in-
creasing rates of stent thrombosis/MI and death in
patients receiving DES [12,13]. However, much of this
has been refuted by careful analysis of larger randomized
groups as well as data from registries [14-16]. In our
study, the stable risks of death and MI following PCI do
not support a clinically significant increase in risk of
stent thrombosis associated with the change from BMS
to DES. The long-term follow-up of our study cohort,
which is currently in progress, will allow us to determine
if there is any evidence to suggest reduced long-term
safety of DES, especially with outcomes of MI and stent
thrombosis.
We also observed a lower adjusted risk of death in the
PCI cohort compared to the CABG cohort in the Cox
regression models. The higher 28-day and one-year mor-
tality in the CABG cohort compared to PCI is not unex-
pected in this non-randomised study and likely reflects
the combination of procedural risk and selection of
patients with more diffuse disease and complex
comorbidities for surgical revascularisation. The lower
proportion of major clinical outcomes (but not TVR) in
the CABG cohort in 2003 (the year following the intro-
duction of DES) is not easily explained by our data.
However, we cannot rule out variation in the proportion
of cases per surgeon in that year, changes to the indica-
tions for surgery, or a shift from CABG to DES for high-
risk cases.
Table 3 Fitted multivariate Cox model for one-year outcomes/endpoints in the total coronary artery revascularisation
cohort from 2000 to 2004
Variable Adjusted hazard ratios (95% CI)
Death Death/MI TVR MACE
Year of procedure:*2000 1.0 1.0 1.0 1.0
2001 0.95 (0.72, 1.27) 0.90 (0.72, 1.13) 0.95 (0.78, 1.16) 0.91 (0.78, 1.07)
2002 1.03 (0.79, 1.36) 0.96 (0.77, 1.20) 0.72 (0.58, 0.89) 0.83 (0.70, 0.97)
2003 0.87 (0.66, 1.15) 0.80 (0.64, 1.00) 0.55 (0.44, 0.69) 0.64 (0.54, 0.75)
2004 1.19 (0.92, 1.55) 1.05 (0.85, 1.29) 0.54 (0.43, 0.67) 0.74 (0.63, 0.87)
Age at index admission 1.06 (1.05, 1.07) 1.04 (1.03, 1.05) 1.00 (1.00, 1.01) 1.02 (1.01, 1.02)
Gender (male) * 0.90 (0.75, 1.09) 0.92 (0.79, 1.08) 0.92 (0.78, 1.08) 0.91 (0.81, 1.03)
Charlson score at index admission 1.31 (1.27, 1.34) 1.28 (1.25, 1.31) 1.06 (1.02, 1.10) 1.19 (1.17, 1.22)
Index principal diagnosis (MI) * 1.24 (1.01, 1.52) 1.13 (0.96, 1.34) 0.83 (0.69, 1.00) 1.00 (0.88, 1.14)
Index admission type (emergency) * 2.04 (1.65, 2.52) 1.88 (1.58, 2.23) 1.18 (1.00, 1.40) 1.45 (1.28, 1.65)
Index hospital type (public) * 1.17 (0.96, 1.43) 1.25 (1.06, 1.47) 0.82 (0.71, 0.96) 0.99 (0.89, 1.11)
Number of vessels treated (multivessel disease) * 1.35 (1.09, 1.66) 1.24 (1.04, 1.47) 1.47 (1.24, 1.76) 1.35 (1.18, 1.54)
CARP type (PCI) * 0.75 (0.60, 0.94) 1.18 (0.97, 1.43) 8.15 (6.05, 10.97) 2.37 (2.03, 2.78)
95% CI 95% confidence interval, MI myocardial infarction, TVR target vessel revascularisation, MACE major adverse cardiac events (death/MI/TVR), CARP coronary
artery revascularisation procedure, PCI percutaneous coronary intervention.
* Baseline levels are year 2000, female, no MI as principal discharge diagnosis in index admission, booked index admission, index admission in a private hospital,
single vessel disease and bypass surgery (CABG).
Age (years) and Charlson score are continuous variables.
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to a significant decrease in TVR over the study
period in the PCI group and all CARP population.
The main driver of TVR is restenosis of the treated
vessel. The threshold at which angiographic restenosis
leads cardiologists to recommend a TVR is not
expected to have changed over the study period, so it
is likely that the observed reduction in TVR repre-
sents a reduction in restenosis. The significance and
importance of TVR as an endpoint, especially com-
pared with death and MI, has been debated widely.
However, data from the SIRIUS trial showed that pa-
tients who have clinically driven TVR have worse
long-term outcomes of death or MI following the
TVR [17]. Therefore its economic, social and clinical
impact should not be underestimated.
In this observational study, we cannot be certain
that there is a causal relationship between the chan-
ging coronary revascularisation strategies and the ob-
served reduction in TVR and stability in rates of
death and MI. However, a unique aspect of our
study cohort was the rapid transition from BMS to
DES during 2002, which resulted in a decline in the
use of BMS from 100% in 2000-2001 to less than
10% in 2003-2004, with a reciprocal increase in the
use of DES. While this rapid uptake of DES was asso-
ciated with changes in case selection for PCI which
could have affected outcomes, bias due to temporal
changes in other medical treatment and case severity
would have been minimised although not totallyexcluded. We have attempted to adjust for such effects by
including calendar year in our multivariate regression
models, in addition to demographic and clinical factors
known to affect outcomes. However, we acknowledge that
since patients undergoing revascularisation in 2000-2004
were not randomly assigned to a treatment year there may
be unknown or unmeasured confounders that might
introduce bias in the calendar year comparisons.
Although there are limitations reflecting complete cap-
ture of past medical history in calculating a comorbidity
score from administrative data, this limitation would not
bias one group over another in our study because we in-
vestigated the total cohort of coronary artery procedures.
All patients in this cohort presented with coronary heart
disease and detection of risk factors and reporting of
past medical history would be consistent for each person
in the cohort. Furthermore, the comorbidities recorded
in our administrative dataset are diagnoses made by doc-
tors as recorded in medical notes. The Charlson score as
a single measure of comorbidity had an area under the
ROC curve of about 70% (range 65.6-75.5) for predicting
one-year mortality [18], with the predictive ability im-
proving after adjusting for age and sex [18], as we have
done in our regression models.
A major strength of our study is the inclusiveness of
our cohort (all index CARP) and complete data on out-
comes and endpoints in the follow-up period from both
clinical and administrative data sources. Pivotal to this is
our linkage of procedural data to routinely collected
hospital admission and mortality data which allows
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follow-up of patients. There is no reason to suggest that
our findings are only applicable to the Australian popu-
lation. The revascularisation technologies in use in
Australia over that time period, as well as in current
times, are the same as were available in other countries.
Therefore, the results of our population-based analysis
are applicable in other jurisdictions throughout the
world. The transition from BMS to DES was universal
during this period and therefore this analysis is not only
a reflection of an Australian population, but should also
be a reflection of practice throughout the world.
Conclusions
In summary, changing coronary revascularisation strat-
egies related to the introduction of DES were not associ-
ated with changes in one-year risk of major clinical
endpoints (death or death/MI), but were associated with
a significant reduction in the risk of MACE, driven en-
tirely by a reduction in TVR after PCI. This real world
study supports the effectiveness of DES in reducing re-
peat procedures in the total CARP population without
increasing the risk of death or MI. Our current very
long-term follow-up of the study cohort will allow ana-
lysis well beyond the early risk period of one year, and
provide population-based evidence of any long-term
benefits of care and cost-effectiveness in the
revascularisation population.
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